arrow
K

Kenta Murotani

kurume university
H指数:45
被引数:7,695

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival impact of pelvic radiotherapy plus chemotherapy in newly diagnosed stage IVB cervical cancer in Japan (JROSG22-1/JGOG1088S)

日本新诊断IVB期宫颈癌患者接受盆腔放疗联合化疗的生存影响(JROSG22-1/JGOG1088S)

2026-09-010
PRE
Long-term efficacy and safety of romiplostim plus immunosuppressive therapy as first-line treatment in patients with aplastic anaemia: 2-year interim analysis of observational study of two clinical trials

罗米司亭联合免疫抑制疗法作为再生障碍性贫血患者的一线治疗的长期疗效和安全性:两项临床试验的观察性研究的2年中期分析

2026-08-210
OAAI
Ocular pharmacokinetics of tivozanib eye drops in patients with neovascular age-related macular degeneration: comparison with phase 1 trials of oral tivozanib in solid tumors

玻璃体内注射tivozanib滴眼液在新生血管性年龄相关性黄斑变性患者中的眼内药代动力学:与实体瘤口服tivozanib的I期临床试验比较

2026-04-150
OA
The Efficacy of Imeglimin and Metformin on Insulin Sensitivity and Secretion Using Oral Minimal Model: Sub-Analysis of an Exploratory Randomised Controlled Trial

Imeglimin和Metformin对胰岛素敏感性和分泌的疗效:一项探索性随机对照试验的亚组分析(使用口服最小模型)

2026-03-190
OAAI
BALLAST study: A multicentre, open-label, randomized-controlled, 52-week clinical trial of the efficacy and safety of luseogliflozin in older Japanese adults with type 2 diabetes receiving leucine-enriched amino acid supplementation and physical exercise programme
2026-01-210
OAAI
Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo)

日本转移性结直肠癌患者中,FOLFIRI联合低剂量伊立替康与雷莫芦单抗作为二线治疗的II期研究(研究rindo)

2025-12-010
OA
Electrophysiological diagnosis using the coefficient of variation of R-R intervals and a point-of-care nerve conduction device is highly correlated to the diagnosis of diabetic polyneuropathy using conventional electromyographs

使用R-R间期变异系数和床旁神经传导装置进行的电生理诊断,与使用常规肌电图进行的糖尿病多发性神经病变诊断高度相关。

2025-11-010
OAAI
Effects of Three Different Ureteral Stents on Stent-Related Symptoms in Patients Undergoing Ureteroscopic Lithotripsy: Assessment Using the Ureteral Stent Symptoms Questionnaire

三种不同输尿管支架对输尿管镜碎石术患者支架相关症状的影响:采用输尿管支架症状问卷进行评估

2025-10-310
PRE
Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab

可溶性免疫介质与不可切除的III期非小细胞肺癌患者同步放化疗后联合durvalumab治疗结局的关系

2025-10-310
PRE
Volume histogram analysis of whole-lung CT: differentiating usual from nonspecific interstitial pneumonias and predicting prognosis

全肺CT体积直方图分析:区分普通型与非特异性间质性肺炎并预测预后

2025-10-100
OA
Machine learning–based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors

基于机器学习的循环自身抗体动力学和治疗结局在NSCLC接受免疫检查点抑制剂治疗患者中的洞察

2025-10-030
OAAI
Prospective Multicenter Registry to Investigate the Clinical Feasibility of Combination Workflow With 90 W/4 s and Ablation Index-Guided 50 W Ablation (PRECISE-COMBO 90 W/50 W Study)

前瞻性多中心登记研究,旨在探讨联合工作流程(90 W/4 s 与消融指数引导的50 W消融)的临床可行性(PRECISE-COMBO 90 W/50 W 研究)

2025-10-010
OAAI
Self-reported sleep variables, sleep quality, and quality of life assessment in transition to lemborexant in patients with Insomnia: the multicenter, open-label SOMNUS study

患者自报的睡眠变量、睡眠质量以及生活质量评估在转换为雷美雷酮治疗失眠过程中的应用:一项多中心、开放标签的SOMNUS研究

2025-10-010
OAAI
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study

免疫检查点抑制剂诱导的间质性肺病(合并与不合并CTLA-4方案)在PD-L1 < 1 %的非小细胞肺癌患者中的研究:一项多中心、回顾性研究

2025-09-260
PRE
A new hyaluronate gel spacer and injection technique for cervical cancer brachytherapy: a technical report

一种新型透明质酸盐凝胶间隔器和注射技术用于宫颈癌近距离放射治疗:一份技术报告

2025-09-010
OAAI